Dopamine receptor antagonists - Pipeline Insight, 2024

This “Dopamine receptor antagonists - Pipeline Insight, 2024” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Dopamine receptor antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Dopamine receptor antagonists Understanding

Dopamine receptor antagonists: Overview

Dopamine exerts its effect via a family of cell surface G protein-coupled receptors (GPCRs), classified as D1-like (ie, D1 and D5) and D2-like (ie, D2, D3 and D4). Among these receptors, D1, D3 and D4 receptors interact with the renin-angiotensin-aldosterone system (RAAS), whereas the D2 and D5 receptors interact with the sympathetic nervous system. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as Antiemetics, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with Neuroleptic Malignant Syndrome.

Dopamine receptor antagonists - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Dopamine receptor antagonists pipeline landscape is provided which includes the disease overview and Dopamine receptor antagonists treatment guidelines. The assessment part of the report embraces, in depth Dopamine receptor antagonists commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Dopamine receptor antagonists collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Dopamine receptor antagonists R&D. The therapies under development are focused on novel approaches to treat/improve Dopamine receptor antagonists.

Dopamine receptor antagonists Emerging Drugs Chapters

This segment of the Dopamine receptor antagonists report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Dopamine receptor antagonists Emerging Drugs

Iloperidone: Vanda Pharmaceuticals Iloperidone is approved for the treatment for Schizophrenia but is currently in Phase III stage of development for the treatment of Bipolar disorders. It acts as antagonists of Dopamine D2 receptor and Serotonin 2 receptor.

NG101: Neurogastrx NG101 is a potent, selective and peripherally restricted dopamine D2 receptor antagonist currently in Phase II clinical development for the treatment of gastroparesis. Neurogastrx has generated preclinical data indicating that in addition to its potent antiemetic properties, NG101 is also expected to significantly increase gastric motility, conferring NG101 an ideal pharmacological profile for the treatment ofgastroparesis

Dopamine receptor antagonists: Therapeutic Assessment

This segment of the report provides insights about the different Dopamine receptor antagonists drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Dopamine receptor antagonists

There are approx. 25+ key companies which are developing the therapies for Dopamine receptor antagonists. The companies which have their Dopamine receptor antagonists drug candidates in the most advanced stage, i.e. Phase III include, Vanda Pharmaceuticals.

Phases

This report covers around 25+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Dopamine receptor antagonists pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Dopamine receptor antagonists: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Dopamine receptor antagonists therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dopamine receptor antagonists drugs.

Dopamine receptor antagonists Report Insights

• Dopamine receptor antagonists Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Dopamine receptor antagonists Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Dopamine receptor antagonists drugs?
• How many Dopamine receptor antagonists drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Dopamine receptor antagonists?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Dopamine receptor antagonists therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Dopamine receptor antagonists and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Emalex Biosciences
• Impel NeuroPharma
• Intra-Cellular Therapies
• Vanda Pharmaceuticals
• Neurogastrx

Key Products

• Ecopipam
• INP 105
• ITI-333
• Iloperidone
• NG101

This product will be delivered within 1-3 business days.